ClinicalTrials.gg
Drug

Panobinostat clinical trials

Also written LBH589 and Farydak.

studies test it
136
open now
3
in phase 3
3
first study started
2003

How each study uses Panobinostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Panobinostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Feb 2015 · FARYDAK · NDA 205353 (FDA, Drugs@FDA)
European Union
28 Aug 2015 · Farydak · EMEA/H/C/003725 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Panobinostat
92
Faridak
8
Panobinostat (LBH589)
8
HDAC inhibitor LBH589
5
histone deacetylase inhibitor LBH589
5

Brand

Farydak
12

Development codes

LBH589
87

Studies by the year they started

135 studies that test it; most in 2009 (30)

Studies that test Panobinostat, by start year
YearStudies
20031
20063
200712
200820
200930
201021
201114
20127
20135
20142
20152
20169
20172
20182
20192
20211
20221
20241

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
78
Phase 2
78
Phase 3
3
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 43 · Other 93

Novartis Pharmaceuticals (40) · M.D. Anderson Cancer Center (7) · H. Lee Moffitt Cancer Center and Research Institute (7) · SCRI Development Innovations, LLC (6) · Dana-Farber Cancer Institute (3) · City of Hope Medical Center (3) · Massachusetts General Hospital (2) · Mayo Clinic (2)

Often tested with

Tested in the same studies.

Dexamethasone (7) · Bortezomib (6) · Carfilzomib (5) · Lenalidomide (4) · Ruxolitinib (3) · Gemcitabine (3) · Everolimus (3) · Busulfan (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Panobinostat.

Studies

Open first, then newest update. How each study uses Panobinostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 136

See all 136 studies that test Panobinostat →

Given beside what is tested · 8 — Panobinostat is usual care or a partner of the new treatment

Codes

What other systems call Panobinostat · ClinicalTrials.gg INT006802

  • MeSH (NLM) D000077767PanobinostatConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 9647FM7Y3ZPANOBINOSTATConfirmed FDA, NLM, Wikidata
  • RxNorm 1603350Confirmed FDA, Wikidata
  • Wikidata Q7131441panobinostatConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C66948PanobinostatOne source FDA
  • DrugBank DB06603One source Wikidata

Also registered as panobinostat hydrate (UNII D07V79Q44T) and panobinostat lactate (UNII HN0T99OO4V · RxNorm 1603349).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.